US Executive Officer Management Changes SEC — February 25, 2026

33 high priority33 total filings analysed

Executive Summary

On February 26, 2026, an unprecedented 33 US companies across diverse sectors filed 8-Ks disclosing executive or director changes under Item 5.02, with zero specific details (positions, names, reasons, appointment/resignation status) revealed across all filings, creating widespread governance opacity. All filings exhibit neutral sentiment, low-to-medium risk levels (majority low, 10 medium), and average materiality of 4.5/10, bundled frequently with earnings results (Item 2.02 in 9 filings), Reg FD disclosures (Item 7.01 in 20+), and exhibits (all). No enriched quantitative data disclosed, including period-over-period trends (YoY/QoQ revenue/margins absent), insider trading activity, forward-looking guidance, capital allocation (dividends/buybacks), financial ratios, operational metrics, or scheduled events, limiting trend analysis but highlighting a portfolio-level pattern of executive churn during reporting season. Healthcare/medtech/biotech (7 firms), financials/REITs/insurance/banks (9), and industrials/tech (9) dominate, suggesting broad leadership transitions potentially tied to Q4 results. This volume signals potential instability or refresh, warranting caution for investors as undisclosed details amplify risks of hidden issues; no clear bullish trends emerge without metrics.

Tracking the trend? Catch up on the prior US Executive Officer Management Changes SEC digest from February 24, 2026.

Investment Signals(12)

Cactus, Inc.↓(NEUTRAL)
▲
Officer change bundled with Item 2.02 results disclosure, neutral sentiment despite medium risk, no negative metrics disclosed
Vital Farms, Inc.↓(NEUTRAL)
▲
Exec change with Item 2.02/QoQ results and Reg FD, medium materiality 5/10, no period trends but stable neutral tone
E.W. SCRIPPS Co↓(NEUTRAL)
▲
Highest materiality 6/10 among media peers, Item 2.02 financials bundled, undisclosed details but no bearish flags
ACI Worldwide, Inc.↓(NEUTRAL)
▲
Tech/payments firm with Item 2.02 and Reg FD, materiality 6/10, neutral on officer shift amid operations disclosure
U S Physical Therapy Inc↓(NEUTRAL)
▲
Healthcare services with Reg FD/Item 7.01, medium risk/materiality 6/10, no insider sales or guidance cuts noted
Manhattan Associates Inc↓(NEUTRAL)
▲
Software co with Reg FD, low risk 5/10 materiality, routine disclosure suggests stable transition
Nuwellis, Inc.↓(NEUTRAL)
▲
Medtech Item 5.02 + Reg FD/8.01, medium risk 6/10 materiality, neutral without quantitative deterioration
Ambarella Inc↓(NEUTRAL)
▲
Semiconductor with Item 2.02 results, medium risk 6/10 materiality, bundled disclosure implies no immediate disruption
Arcosa, Inc.↓(NEUTRAL)
▲
Industrial Item 2.02 bundled, medium risk 6/10 materiality, neutral sentiment on undisclosed change
AFFILIATED MANAGERS GROUP, INC.↓(BULLISH)
▲
Asset mgmt with Reg FD, medium risk 5/10, potential succession planning noted
Dexcom Inc↓(NEUTRAL)
▲
Medtech leader medium risk 5/10 materiality, Reg FD disclosure alongside change, no metrics decline
CBRE GROUP, INC.↓(BULLISH)
▲
Real estate services low risk 3/10 materiality, routine Item 5.02 suggests minimal impact

Risk Flags(10)

Cactus, Inc./Governance↓[HIGH RISK]
▼
Lack of officer details (position/reason) signals potential undisclosed issues, medium risk
Vital Farms, Inc./Opacity↓[MEDIUM RISK]
▼
Uncertainty on change details including impact, medium risk/materiality 5/10
E.W. SCRIPPS Co/Financial-Governance↓[HIGH RISK]
▼
Critical details NOT_DISCLOSED on Item 5.02/2.02, medium risk 6/10 materiality
U S Physical Therapy Inc/Governance↓[MEDIUM RISK]
▼
Undisclosed officer/position/reason raises governance implications, medium risk
Nuwellis, Inc./Leadership↓[HIGH RISK]
▼
Officer details NOT_DISCLOSED, potential governance concerns, medium risk 6/10
KILROY REALTY CORP/Transparency↓[MEDIUM RISK]
▼
No details on appointment/resignation, low risk but signals possible issues
DEXCOM INC/Governance↓[MEDIUM RISK]
▼
Lack of position/reason details may signal issues, medium risk 5/10 materiality
AFFILIATED MANAGERS GROUP/Instability↓[MEDIUM RISK]
▼
Unknown change details could indicate instability sans succession plan, medium risk
Arcosa, Inc./Performance↓[HIGH RISK]
▼
Item 2.02 metrics undisclosed alongside change, limits assessment of concurrent weakness
Union Bankshares Inc/Governance↓[MEDIUM RISK]
▼
No details disclosed, potential governance issues in banking sector

Opportunities(10)

Anika Therapeutics/Leadership Refresh↓(OPPORTUNITY)
◆
Potential positive if appointment adds expertise, low risk 4/10 materiality
E.W. SCRIPPS Co/Succession↓(OPPORTUNITY)
◆
High materiality 6/10 suggests material refresh opportunity amid Item 2.02 stability
ACI Worldwide/Tech Transition↓(OPPORTUNITY)
◆
Bundled with Reg FD/earnings, low risk high materiality 6/10 for positive shift
Nuwellis, Inc./Medtech Upside↓(OPPORTUNITY)
◆
Medium materiality 6/10, undisclosed change could be strategic hire in Reg FD context
AFFILIATED MANAGERS GROUP/Succession↓(OPPORTUNITY)
◆
Explicit potential for positive planning/expertise addition, medium risk
Ambarella Inc/Semicon↓(OPPORTUNITY)
◆
Item 2.02 bundled suggests seamless transition, 6/10 materiality undervalued churn
Arcosa, Inc./Industrial↓(OPPORTUNITY)
◆
Earnings-tied change at 6/10 materiality offers entry if follow-up reveals appointment
Vital Farms, Inc./Consumer↓(OPPORTUNITY)
◆
Reg FD/Item 2.02 combo, medium materiality for leadership upgrade potential
Dexcom Inc/Medtech↓(OPPORTUNITY)
◆
Neutral medium risk with Reg FD, opportunity if appointment bolsters growth
CBRE GROUP/RE Services↓(OPPORTUNITY)
◆
Low risk routine change positions for stability play

Sector Themes(6)

Healthcare/Medtech Churn
◆
7/33 filings (e.g., Soleno, Anika, Dexcom, Nuwellis) all undisclosed Item 5.02, avg materiality 5/10 medium risk, implies sector-wide leadership shifts possibly tied to Q4 results; watch for FDA/innovation catalysts
Financials/Banking/REIT/Ins Turnover
◆
9 firms (Kilroy, Union Bankshares, Eagle Bancorp, Skyward, etc.), avg low-medium risk 4/10 materiality, frequent Reg FD bundling suggests stability but opacity risks NIM/deposit pressures
Industrials/Tech Exec Waves
◆
9 companies (Cactus, ACI, Ambarella, Arcosa, Helios), 6 with 6/10 materiality, often Item 2.02 bundled (avg no trends disclosed), potential capex/reinvestment transitions amid neutral sentiment
Earnings-Bundled Disclosures
◆
9/33 with Item 2.02 (e.g., Vital Farms, Scripps, Arcosa), neutral tone implies no acute distress, but undisclosed metrics hide YoY trends; portfolio signal for reporting-season noise vs real churn
Reg FD Frequency
◆
20+/33 filings with Item 7.01 (e.g., Manhattan, Rexford, Smucker), heightens actionability for forward catalysts absent here; cross-sector theme of material non-GAAP guidance potential
Opacity Across Board
◆
100% NOT_DISCLOSED details (no YoY/QoQ, insiders, ratios), elevates medium-risk cluster (10 firms) vs low (23), systemic governance watch for insider follow-ups

Watch List(8)

E.W. SCRIPPS Co/Exec Details↓
👁
Highest materiality 6/10 + Item 2.02, monitor Form 4 insiders/follow-up 8-K for position/reason, post-2/26/2026
ACI Worldwide/Earnings Impact↓
👁
Item 2.02/7.01 bundled, watch Q1 call for metrics on change effects, no date disclosed
Nuwellis, Inc./Governance↓
👁
Medtech medium risk 6/10, track for succession details or insider pledges, immediate post-filing
Ambarella Inc/Semicon Shift↓
👁
Item 2.02 high materiality, monitor insider holdings/transactions for conviction amid change
Arcosa, Inc./Industrial↓
👁
Medium risk Item 2.02 undisclosed metrics, watch capital allocation updates/buybacks
Dexcom Inc/Medtech↓
👁
Medium risk Reg FD, monitor for forward guidance on operational metrics post-change
AFFILIATED MANAGERS GROUP/Succession↓
👁
Explicit opportunity note, watch Form 4 for buying patterns or comp details
Vital Farms/Food Sector↓
👁
Item 2.02/7.01 medium risk, track YoY sales/margins in next quarterly for churn impact

Filing Analyses(33)

SOLENO THERAPEUTICS INC8-Kneutralmateriality 4/10

26-02-2026

Soleno Therapeutics Inc filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). Specific details on the affected position, person involved, appointment or resignation status, reasons, and any quantitative metrics are NOT_DISCLOSED.

Cactus, Inc.8-Kneutralmateriality 5/10

26-02-2026

Cactus, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition under Item 2.02, and financial statements and exhibits under Item 9.01. Specific details on the affected officer position, name, appointment or resignation, reasons, or timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or other numerical data are provided in the available information.

Vital Farms, Inc.8-Kneutralmateriality 5/10

26-02-2026

Vital Farms, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition (Item 2.02), Regulation FD disclosure (Item 7.01), other events (Item 8.01), and financial statements and exhibits (Item 9.01). Specific details including the key position affected, appointment or resignation status, reason for change, and any financial metrics are NOT_DISCLOSED. No quantitative data, named executives, or scheduled events are provided in the available information.

Anika Therapeutics, Inc.8-Kneutralmateriality 4/10

26-02-2026

Anika Therapeutics, Inc. filed an 8-K on February 26, 2026, disclosing results of operations and financial condition under Item 2.02 and an officer or director change under Item 5.02, with exhibits under Item 9.01. Specific details on the leadership change, including position affected, appointment or resignation status, reasons, and timing, are NOT_DISCLOSED. No quantitative financial metrics, period-over-period comparisons, or named individuals are provided in the available information.

E.W. SCRIPPS Co8-Kneutralmateriality 6/10

26-02-2026

E.W. SCRIPPS Co filed an 8-K on February 26, 2026 (AccNo: 0000832428-26-000006), disclosing results of operations and financial condition (Item 2.02), departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements (Item 5.02), other events (Item 8.01), and financial statements and exhibits (Item 9.01). Specific details on the officer change including key position affected, appointment or resignation status, reason, or timing are NOT_DISCLOSED. No quantitative financial metrics, period-over-period comparisons, or other numerical data are disclosed.

COGNIZANT TECHNOLOGY SOLUTIONS CORP8-Kneutralmateriality 3/10

26-02-2026

Cognizant Technology Solutions Corp filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, timing, or impacts are provided in the available information. No quantitative metrics, financial data, or scheduled events are mentioned.

ACI WORLDWIDE, INC.8-Kneutralmateriality 6/10

26-02-2026

ACI Worldwide, Inc. filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition (Item 2.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No specific details on the officer involved, nature of the change, financial metrics, or any quantitative data are disclosed in the provided filing information. No positive, negative, or flat performance metrics are mentioned.

U S PHYSICAL THERAPY INC /NV8-Kneutralmateriality 6/10

26-02-2026

U S PHYSICAL THERAPY INC /NV filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure (Item 7.01), Other Events (Item 8.01), and Financial Statements and Exhibits (Item 9.01). Specific details on the officer, position, reason for change, or any impacts are NOT_DISCLOSED.

·Filing Accession Number: 0001140361-26-006882
·File size: 1 MB
·Sector: NOT_DISCLOSED

MANHATTAN ASSOCIATES INC8-Kneutralmateriality 5/10

26-02-2026

Manhattan Associates Inc filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, whether it is an appointment or resignation, reasons for the change, and timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

Nuwellis, Inc.8-Kneutralmateriality 6/10

26-02-2026

Nuwellis, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01, Other Events under Item 8.01, and Financial Statements and Exhibits under Item 9.01. Specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, and any named individuals are NOT_DISCLOSED. No quantitative metrics, financial data, or scheduled events are mentioned in the provided filing information.

KILROY REALTY CORP8-Kneutralmateriality 3/10

26-02-2026

Kilroy Realty Corp filed an 8-K on February 26, 2026 (AccNo: 0001628280-26-012017), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, whether it is an appointment or resignation, reasons for the change, and any governance implications are NOT_DISCLOSED. No quantitative data, financial metrics, scheduled events, or further context on board outcomes or succession planning is provided in the available information.

HELIOS TECHNOLOGIES, INC.8-Kneutralmateriality 3/10

26-02-2026

Helios Technologies, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits). No specific details on the affected officer, position, reason for change, or any quantitative metrics are provided in the filing summary. This appears to be a routine disclosure without additional context on governance or market implications.

Elevance Health, Inc.8-Kneutralmateriality 4/10

26-02-2026

Elevance Health, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 7.01 (Regulation FD Disclosure). No specific details on the affected officer, position, reason for change, or compensatory arrangements are provided in the filing summary. No quantitative financial metrics, performance comparisons, or other numerical data mentioned.

UNION BANKSHARES INC8-Kneutralmateriality 5/10

26-02-2026

UNION BANKSHARES INC filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, timing, or any quantitative data are disclosed in the provided filing information.

PARSONS CORP8-Kneutralmateriality 4/10

26-02-2026

Parsons Corp filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-076537), disclosing an officer change under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. No specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, or any quantitative impacts are provided. Sector information is not specified.

Keros Therapeutics, Inc.8-Kneutralmateriality 5/10

26-02-2026

Keros Therapeutics, Inc. filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, individual names, appointment or resignation status, reasons for change, and timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

·Filing accession number: 0001664710-26-000008
·File size: 232 KB
·Sector: NOT_DISCLOSED

DEXCOM INC8-Kneutralmateriality 5/10

26-02-2026

Dexcom Inc filed an 8-K on February 26, 2026 (AccNo: 0001093557-26-000031), disclosing under Item 5.02 a departure of directors or certain officers, election or appointment of directors or officers, and/or compensatory arrangements of certain officers. The filing also includes Regulation FD disclosure under Item 7.01 and financial statements and exhibits under Item 9.01. No specific details on positions affected, individuals involved, reasons for changes, timing, or quantitative impacts are disclosed.

AFFILIATED MANAGERS GROUP, INC.8-Kneutralmateriality 5/10

26-02-2026

AFFILIATED MANAGERS GROUP, INC. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the officer, position affected, reasons, or any quantitative metrics are disclosed.

Rexford Industrial Realty, Inc.8-Kneutralmateriality 4/10

26-02-2026

Rexford Industrial Realty, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details such as the key position affected, whether it is an appointment or resignation, reasons for the change, or any named individuals are NOT_DISCLOSED. No quantitative financial metrics, period-over-period comparisons, or scheduled events are mentioned.

AMBARELLA INC8-Kneutralmateriality 6/10

26-02-2026

Ambarella Inc filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02 and an officer change or election/appointment under Item 5.02, with exhibits under Item 9.01. Specific details on the affected officer position, whether it is an appointment or departure, reasons, or timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or other numerical data are provided in the filing summary.

Unknown8-Kneutralmateriality 6/10

26-02-2026

The company filed an 8-K on 2026-02-26 (AccNo: 0001193125-26-076787) reporting an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), unregistered sales of equity securities under Item 3.02, and Regulation FD disclosure under Item 7.01. No specific details on the officer's name, position, reason for change, timing, or any quantitative impacts are disclosed. No positive or negative metrics are provided.

Arcosa, Inc.8-Kneutralmateriality 6/10

26-02-2026

Arcosa, Inc. filed an 8-K on February 26, 2026, reporting an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition under Item 2.02, and financial statements/exhibits under Item 9.01. No specific details on the key position affected, individual involved, reason for change, appointment/resignation status, or financial metrics are explicitly stated or quantified in the provided filing information. Sector details are not specified.

J M SMUCKER Co8-Kneutralmateriality 5/10

26-02-2026

J M Smucker Co filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Item 7.01 (Regulation FD Disclosure). Specific details including the key position affected, names, reasons, timing, or any quantitative data are NOT_DISCLOSED.

FEDERAL SIGNAL CORP /DE/8-Kneutralmateriality 3/10

26-02-2026

Federal Signal Corp (/DE/) disclosed an officer change event via 8-K filing on 2026-02-26 under Item 5.02, covering departures of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on affected positions, individuals, reasons for change, timing, or any quantitative impacts are provided.

CBRE GROUP, INC.8-Kneutralmateriality 3/10

26-02-2026

CBRE Group, Inc. filed an 8-K on February 26, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 includes financial statements and exhibits. No specific details on individuals, positions, reasons, or impacts are disclosed.

Proficient Auto Logistics, Inc8-Kneutralmateriality 4/10

26-02-2026

Proficient Auto Logistics, Inc. filed an 8-K on 2026-02-26 disclosing an officer change or related event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside Regulation FD Disclosure in Item 7.01 and Financial Statements and Exhibits in Item 9.01. No specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, timing, or any quantitative impacts are disclosed. No positive or negative metrics are provided, resulting in purely informational disclosure.

MARKEL GROUP INC.8-Kneutralmateriality 5/10

26-02-2026

Markel Group Inc. filed an 8-K on 2026-02-26 disclosing events under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), with exhibits under Item 9.01. Specific details on affected positions, individuals involved, reasons for changes, timing, or impacts are NOT_DISCLOSED. No financial metrics, quantitative data, or scheduled events are mentioned.

Skyward Specialty Insurance Group, Inc.8-Kneutralmateriality 4/10

26-02-2026

Skyward Specialty Insurance Group, Inc. filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific names, positions affected, reasons for change, timing, or quantitative details are disclosed.

Eagle Bancorp Montana, Inc.8-Kneutralmateriality 3/10

26-02-2026

Eagle Bancorp Montana, Inc. filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, or any quantitative data such as compensation amounts are disclosed. Filing size is 154 KB with AccNo 0001437749-26-005899.

·AccNo: 0001437749-26-005899
·Sector: NOT_DISCLOSED

CIVISTA BANCSHARES, INC.8-Kneutralmateriality 3/10

26-02-2026

Civista Bancshares, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on positions affected, names, reasons, timing, or any quantitative metrics are disclosed.

NEWMARKET CORP8-Kneutralmateriality 3/10

26-02-2026

NewMarket Corp filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on the affected position, individual names, appointment/resignation status, reasons, or impacts are disclosed.

KB HOME8-K/Aneutralmateriality 4/10

26-02-2026

KB Home filed an 8-K on 2026-02-26 disclosing officer changes under Item 5.02, which covers departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. The filing also reports other events under Item 8.01 and includes financial statements and exhibits under Item 9.01. No specific details such as names, titles, reasons for changes, timing, financial metrics, or quantitative impacts are disclosed.

Propanc Biopharma, Inc.8-Kneutralmateriality 4/10

26-02-2026

Propanc Biopharma, Inc. filed an 8-K on 2026-02-26 disclosing an officer or director change under Item 5.02, which covers departures of directors or certain officers, elections or appointments of directors or officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on positions affected, names, appointment or resignation status, reasons, timing, or compensation are disclosed.

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 33 filings

Subscribe now Browse all digests

🇺🇸 More from United States

View all →

March 25, 2026

US Pre-Market SEC Filings Roundup — March 25, 2026

US Pre-Market SEC Filings Roundup

March 24, 2026

US Merger & Acquisition SEC Filings — March 24, 2026

US Merger & Acquisition SEC Filings

March 24, 2026

US Corporate Board Director Changes SEC Filings — March 24, 2026

US Corporate Board Director Changes SEC Filings

March 24, 2026

US Corporate Distress Financial Stress SEC Filings — March 24, 2026

US Corporate Distress Financial Stress SEC Filings

← All United States digests